在心力衰竭中使用单片药 (多片药) 组合疗法的态度:患者和医生的观点
Jan Biegus1,2, Rafał Tymków1, Javed Butler3,4
1Jan Mikulicz Radecki University Hospital in Wrocław, Poland.
ESC heart failure
|February 19, 2026
概括
医生和心力衰竭患者强烈支持单片药物组合 (SPC),以简化治疗并减少药物负担. 这表明需要开发心力衰竭 (HF) 多药药策略.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 患者的坚持 患者的坚持
背景情况:
- 心力衰竭 (HF) 患者经常管理多种药物,导致显著的药物负担和坚持挑战.
- 单片组合药物 (SPC) 在其他心血管领域是有效的,但目前无法为HF患者提供.
- 一个特定于HF的SPC可以简化治疗方案并改善患者的治疗结果.
研究的目的:
- 评估医生和患者对潜在的单片组合药 (SPC) 的态度,以治疗心力衰竭 (HF),喷射分数≤50%.
- 确定指南导向医疗疗 (GDMT) 优化的障碍,并为HF特定的SPC提供首选组件.
主要方法:
- 两项前性电子调查 (2025年6月至10月) 针对医生和患有HF的患者进行.
- 医生调查探讨了GDMT的实践,需求,障碍和首选的SPC组成.
- 患者调查评估了药物负担,药物坚持以及对多药丸使用的看法.
主要成果:
- 大多数医生 (77%) 认为需要简化GDMT,并将成本和多药作为关键障碍.
- 95%的医生认为临床上需要HF特定的SPC,认为它在临床上是有用的 (88%) 和可行的 (76%).
- 大多数患者 (75%) 报告说,由于多药性 (每天≥6种药物) 导致偶尔不遵守药物;如果提供,83%的患者会服用HF特定的SPC,特别是没有额外费用.
结论:
- 医生和患者都表达了强烈的意愿和对HF特定SPC的开放.
- 这些发现支持进一步开发和评估用于心力衰竭管理的多药药策略.
相关概念视频
01:30Heart Failure V: Medical Management
388
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
388
01:22Heart Failure Drugs: β-Blockers
992
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
992
01:27Coronary Artery Disease V: Interprofessional Care
320
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
320
01:28Drug Therapy
316
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
316
01:15Drug Dosing: Geriatric Patients
306
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
306
01:22Heart Failure VI: Adjunct Therapies
428
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
428